Symbols

BCRX

BioCryst Pharmaceuticals·NASDAQ

--(--)

BCRX fundamentals

BCRX Q4 2025 Earnings

BioCryst Pharmaceuticals (BCRX) released its earnings on Feb 26, 2026: revenue was 406.56M (YoY +209.09%), beat estimates; EPS was 1.12 (YoY +961.54%), beat estimates.

Revenue / YoY

406.56M

+209.09%

EPS / YoY

1.12

+961.54%

Report date

Feb 26, 2026

BCRX Earnings Call Summary for Q4,2025

Revenue Growth: ORLADEYO up 43% YoY, driving $214M operating profit.
HAE Portfolio Expansion: Launches ORLADEYO pellets for kids, Navenibart Phase II shows 92% attack reduction.
2026 Outlook: $625-645M revenue, 4x ROI on sales spend, $400M credit facility for M&A flexibility.
Strategic Focus: Build durable HAE franchise with 3 distinct prophylaxis options; rare disease pipeline expansion.

Earnings

EPS

Revenue

Revenue & Expenses

BCRX has released its 2025 Q4 earnings report, with revenue of 406.56M, reflecting a YoY change of 209.09%, and net profit of 245.84M, showing a YoY change of 1017.50%. The Sankey diagram below clearly presents BCRX's revenue sources and cost distribution.

Key Indicators

BioCryst Pharmaceuticals (BCRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BioCryst Pharmaceuticals (BCRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BioCryst Pharmaceuticals (BCRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BioCryst Pharmaceuticals (BCRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown